LFA-1

Lifitegrast (SAR 1118) is an antagonist of lymphocyte function-associated antigen-1.

A 286982 is an inhibitor that blocks the integrin-ligand interaction between leukocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1.

The Anti-CD11a/LFA-1α Antibody (R7-1) is a chimeric mouse IgG1 antibody specifically targeting human CD11a/LFA-1α. The recommended isotype control for this antibody is Mouse IgG1 kappa, Isotype Control.

The Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13) is a chimeric mouse IgG1 antibody targeting LFA-1α/CD11a of human origin. Its isotype control is designated as MouseIgG1kappa, Isotype Control.

Anti-Mouse CD11a/LFA-1α Antibody (M17/4) is a rat IgG2a kappa monoclonal antibody specifically targeting CD11a/LFA-1α in mouse models. The recommended isotype control for this antibody is 'Rat IgG2a kappa, Isotype Control'.

RWJ 50271 is a selective lymphocyte function-associated antigen-1/intercellular adhesion molecule-1(LFA-1/ICAM-1) interaction inhibitor( IC50 of 5.0 μM in HL60 cells).

BI-1950 is a highly potent inhibitor of lymphocyte function-associated antigen-1 (LFA-1), an essential component in normal immune system function and a significant target for drug discovery [1].

BMS-688521 BMS-688521 is an orally active and potent inhibitor of LFA-1 ICAM interaction, a small molecule antagonist of leukocyte function-associated antigen-1 (LFA-1), with potential anti-inflammatory activity.

BIRT-377 is a negative allosteric and orally bioavailable inhibitor of ICAM-1 and LFA-1(Ki = 25.8 nM). BIRT-377 inhibits the production of IL-2 and can be used in studies about inflammatory and immune disorders.

ICAM-1988 is a LFA-1 antagonist.

BMS-587101 is a small molecule antagonist of LFA-1, which can reduce inflammation and joint destruction in the mouse model of arthritis.

XVA143, an α β I-like allosteric antagonist, effectively blocks LFA-1-dependent firm adhesion while simultaneously increasing adhesion under shear flow and rolling conditions, both in vitro and in vivo.

Efalizumab, a novel potent regulator of T cells, is a humanized LFA-1 α subunit (CD11a) monoclonal antibody. Efalizumab has inhibitory effects on T cell activation, skin T cell transport, and T cell adhesion to keratinocytes, and can be used to study plaque psoriasis and psoriatic arthritis.

Odulimomab (anti-LFA1), an anti-LFA-1 monoclonal antibody, inhibits T lymphocyte proliferation and provides protection against ischemia and reperfusion injury. It is utilized in researching transplant rejection and immunological diseases [1] [2].

Adxanthromycin A is a microbial metabolite and serves as an inhibitor of cell adhesion mediated by ICAM-1 LFA-1.